PD-L1 expression in renal cell tumors. PD-L1 immunostaining is diffuse and strong in a clear cell RCC (a), shows a mosaic pattern in an oncocytoma (b), and—with a higher rate of positive cells—in a chromophobe carcinoma (c). A papillary RCC without tumor cell staining shows abundant ...
Immunotherapies targeting PD-1/PD-L1 are now widely used in the clinic to treat a variety of malignancies. While most of the research on T cell exhaustion and PD-1 blockade has been focused on conventional αβ T cells, the contribution of innate-like T
The blockade of LIF releases the epigenetic silencing of CXCL9 triggering CD8T cell tumor infiltration. The combination of LIF neutralizing antibodies with the inhibition of the PD1 immune checkpoint promotes tumor regression, immunological memory and an increase in overall survival....
tumors were treated with vehicle/anti-hGDF-15/anti-PD-1/anti-hGDF-15+anti-PD1. Representative pictures (p), the percentage of tumor-infiltrating CD8+ T cells (q) and a score for perinecrotic CD8+ T cell infiltration (r) are shown. s,...
这些差异反映在两个亚群的功能能力上。TPE细胞含有增殖能力,产生Tcf1+PD1+和分化的Tcf1-PD1+细胞,而TEX细胞主要表现为细胞溶解功能。总之,这些数据表明,有效的抗肿瘤免疫反应需要TPE细胞和TEX细胞的微妙平衡。因此,来自慢性病毒感染小鼠模型的数据表明...
关键词: CTLA4 PD1 T-cell cancer check-point blockade immune surveillance migration motility DOI: 10.3389/fimmu.2018.02737 年份: 2018 收藏 引用 批量引用 报错 分享 全部来源 免费下载 求助全文 EBSCO 掌桥科研 dx.doi.org NCBI ResearchGate 查看更多 相似文献 参考文献...
Background: Primary central nervous system lymphoma (PCNSL) is a malignant brain tumor with limited treatment options and shows prominent infiltration by tumor infiltrating lymphocytes (TILs) and tumor-associated macrophages (TAMs). Programmed death 1 (PD1; CD279) and its ligand PD-L1 (B7H1, CD27...
cell line HepG2 (HB-8065; RRID: CVCL_0027), the human gastric cancer cell line AGS (CRL-1739; RRID: CVCL_0139), the mouse breast cancer cell line 4T1 (CRL-2539; RRID: CVCL_0125) the mouse gastric cancer cell line MFC (RRID: CVCL_5J48), and the mouse breast cancer cell line ...
Medical fieldAI modelInput dataTumorPrediction performanceImmunotherapyRef Empty CellMedical fieldAI modelInput dataTumorPrediction performanceImmunotherapyRef Hematology ML: RF Immunogenomics 20 solid tumors PD1: AUC = 0.63 (95%CI: 0.49–0.82);PDL1: AUC = 0.56 (95%CI: 0.34–0.77);CTLA4: AUC = ...
a novel anti-PD-L1 T -cell stimulating antibody, inhibits PD-L1-tumor cell growth also by affecting the intracellular MAPK pathway and by activating caspase 3. Similarin vitroresults were obtained for the first time here also with the clinically validated anti-PD-L1 mAb Atezolizumab andin vivo...